uniQure’s (QURE) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of uniQure (NASDAQ:QURE) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $70.00 target price on the biotechnology company’s stock.

A number of other equities analysts also recently commented on QURE. Barclays assumed coverage on shares of uniQure in a research note on Tuesday, January 27th. They set an “equal weight” rating and a $31.00 target price on the stock. Stifel Nicolaus cut their price target on shares of uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, December 11th. Chardan Capital reaffirmed a “buy” rating and set a $53.00 price target on shares of uniQure in a research report on Thursday, December 4th. Royal Bank Of Canada decreased their price objective on uniQure from $65.00 to $45.00 and set an “outperform” rating on the stock in a report on Monday, November 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, January 21st. Ten analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $58.33.

uniQure Stock Performance

NASDAQ QURE opened at $22.37 on Tuesday. The stock’s fifty day moving average is $23.39 and its two-hundred day moving average is $28.98. The firm has a market capitalization of $1.39 billion, a P/E ratio of -5.10 and a beta of 0.66. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. uniQure has a fifty-two week low of $7.76 and a fifty-two week high of $71.50.

uniQure (NASDAQ:QURE) last issued its earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The company had revenue of $3.70 million during the quarter, compared to analyst estimates of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. On average, research analysts anticipate that uniQure will post -3.75 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Robert Gut sold 25,613 shares of uniQure stock in a transaction on Monday, January 12th. The stock was sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the sale, the director directly owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. The trade was a 44.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Jack Kaye sold 6,390 shares of the business’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the sale, the director owned 20,439 shares in the company, valued at $557,575.92. This represents a 23.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.79% of the stock is owned by insiders.

Hedge Funds Weigh In On uniQure

Institutional investors have recently bought and sold shares of the company. Swiss National Bank acquired a new position in shares of uniQure in the second quarter valued at approximately $1,080,000. Sanders Morris Harris LLC purchased a new position in uniQure in the 3rd quarter valued at approximately $5,081,000. Jennison Associates LLC acquired a new position in shares of uniQure in the second quarter worth $1,952,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of uniQure during the second quarter worth $872,000. Finally, JPMorgan Chase & Co. raised its stake in shares of uniQure by 471.7% in the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after acquiring an additional 1,491,486 shares in the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Neutral Sentiment: Profile/coverage unrelated to the litigation but included in the feed (may be ignored by most investors). Sarah Tabrizi
• Negative Sentiment: Kessler Topaz has filed a securities‑fraud class action against uniQure on behalf of investors who bought shares between Sept. 24 and Oct. 31, 2025. Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V. (QURE) – Contact Kessler Topaz Meltzer & Check, LLP
• Negative Sentiment: Multiple firms are soliciting lead‑plaintiff applicants and reminding investors of an April 13, 2026 deadline to join cases tied to the Sept.‑Oct. 2025 class period — signaling coordination of litigation activity. Example reminder from ClaimsFiler. uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. – QURE
• Negative Sentiment: Holzer & Holzer and other firms allege uniQure made false/misleading statements and failed to disclose material issues — specifically that the pivotal study design and comparisons to ENROLL‑HD were not fully FDA‑approved and a BLA delay was likely. INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of uniQure N.V. (QURE) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
• Negative Sentiment: Bloomberg Law and others report investor suits specifically over the delayed Huntington’s drug application — media coverage increases visibility and may accelerate selling pressure. UniQure Investor Sues Over Delayed Huntington’s Drug Application
• Negative Sentiment: Multiple additional plaintiff firms (Rosen, Faruqi, Bernstein Liebhard, Berger Montague, Schall, etc.) have announced investigations or filings — the sheer number of firms increases probability of consolidated litigation and potential legal exposure. Example: Faruqi deadline notice. QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.